Efficacy of Rufinamide in Drug-Resistant Epilepsy: A Meta-analysis
Pediatric Neurology , 04/13/2011
Evidence Based Medicine
Verrotti A et al. – Rufinamide was efficacious in doses up to 45 mg/kg daily when provided as adjunctive therapy in patients with Lennox–Gastaut syndrome and other drug–resistant epilepsies.
- Rufinamide is a new orally active antiepileptic drug that has been found to be effective in the treatment of partial seizures and drop attacks associated with Lennox–Gastaut syndrome.
- Quantitative analysis of the efficacy of this new antiepileptic drug from all double–blind, add–on, randomized, placebo–controlled clinical trials published to date was performed.
- Data from 918 patients were studied.
- Number of patients per study varied from 25 to 262.
